- RedHill Biopharma Ltd RDHL has announced the publication of a new study revealing concerning rates of widespread, physician-directed prescribing of clarithromycin-based regimens for H. pylori infection despite rising rates of antibiotic resistance and prior patient macrolide use.
- The data were published in the journal Digestive Diseases and Sciences.
- The publication notes that over 80% of all prescriptions for H. pylori infection are clarithromycin-based therapies, despite ACG recommendations to avoid clarithromycin triple therapy in patients with any prior macrolide use or in regions where the resistance rate is known to be 15% or above.
- "Such failure rates and resistance have not been seen with Talicia," said Dr. Colin W. Howden, Chief of the Division of Gastroenterology, University of Tennessee Health Science Center.
- Since it does not contain clarithromycin, Talicia can be prescribed first-line without having to be concerned about local clarithromycin resistance, prior macrolide use, or patient CYP2C19 status," Dr. Colin added.
- Talicia is a fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole).
- In November 2019, Talicia was approved by the FDA to treat H. pylori infection in adults.
- Related Link: RedHill Biopharma's Talicia For Bacterial Infections Shows Efficacy Irrespective of Patient BMI.
- Price Action: RDHL shares are up 1.25% at $3.23 during the market session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
